Climb Bio Q2 net loss widens on pipeline advancement
Climb Bio Q2 net loss widens on pipeline advancement
Overview
US biotechnology firm's Q2 net loss widened yr/yr as operating expenses increased
Company completed $110 mln private placement, extending cash runway into H2 2028
R&D and G&A expenses rose due to advancing clinical programs and pipeline development
Outlook
Climb Bio expects to initiate CLYM116 Phase 2 dosing in IgA nephropathy in Q3 2026
Company anticipates data from pMN, ITP, and SLE studies in Q4 2026
Climb Bio expects cash runway to extend into the second half of 2028
Result Drivers
PIPELINE ADVANCEMENT - Co said increased R&D expenses were driven by progress in clinical programs for budoprutug and CLYM116
TRIAL ENROLLMENT AND DATA PRESENTATIONS - Co cited ongoing enrollment and new safety/efficacy data from multiple clinical trials as milestones achieved in Q2
FINANCING SUPPORTS OPERATIONS - Co said recent $110 mln private placement extends cash runway and enables continued clinical development
Company press release: ID:nGNX9dz7FM
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Loss |
| $13.50 mln |
|
Q2 Operating Expenses |
| $15.36 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 15 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Climb Bio Inc is $20.00, about 60.4% above its August 5 closing price of $12.47
Reuters Recommended Reads
Aug 4 - Dianthus Therapeutics Q2 net loss widens as R&D costs rise
Aug 4 - Tyra Biosciences Q2 net loss widens on higher R&D expenses
Aug 5 - Enliven Therapeutics Q2 net loss widens on higher expenses
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)